Background
==========

ARTEMIS was a Phase III, randomised, open-label study assessing efficacy and safety of DRV/r 800/100mg qd versus LPV/r 800/200mg total daily dose (qd or bid) in treatment-naïve HIV-1-infected adults. At 96 wks, DRV/r demonstrated non-inferiority and superiority to LPV/r in virological response. Wk 192 results are reported.

Methods
=======

Patients stratified by baseline (BL) viral load (VL \[HIV-1 RNA\] \< or ≥100,000 copies/mL \[cpm\]) and CD4 cell count (\< or ≥200 cells/mm^3^) were randomised 1:1 to DRV/r qd or LPV/r. Primary efficacy parameter: non-inferiority (≤ --12%) of DRV/r to LPV/r in virological response (VL \<50 cpm, ITT-TLOVR). DRV/r superiority ( ≤ 0%) was assessed if non-inferiority was demonstrated.

Results
=======

689 patients (30% female; mean BL VL 4.85 log~10~ cpm; median CD4 225 cells/mm^3^) were randomised. Overall, significantly more DRV/r than LPV/r patients had VL \<50 cpm at Wk 192, confirming DRV/r qd non-inferiority (p\<0.001) and superiority (p=0.002) (Table [1](#T1){ref-type="table"}). In patients with virological failure (VF; TLOVR non-VF censored) no developing primary PI mutations were identified in either arm; all VFs with paired BL/endpoint phenotypes that were susceptible at BL to amprenavir, atazanavir, indinavir, lopinavir, saquinavir or tipranavir remained susceptible after treatment.

                                                                       DRV/r                 LPV/r                  DRV/r-LPV/r \[95% CI\]
  -------------------------------------------------------------------- ------- ------------- ------- -------------- ------------------------
                                                                       **N**   **%**         **N**   **%**          
                                                                                                                    
  **VL \<50cpm (ITT-TLOVR)**                                                                                        
                                                                                                                    
  All patients                                                         343     68.8          346     57.2           11.6 \[4.4-18.8\]
                                                                                                                    
  BL VL \<100,000                                                      226     69.5          226     60.2           9.3 \[0.5-18.1\]
                                                                                                                    
  BL VL ≥100,000                                                       117     67.5          120     51.7           15.9 \[3.5-28.3\]
                                                                                                                    
  BL CD4 \<200                                                         141     65.2          148     54.1           11.2 \[-0.1-22.5\]
                                                                                                                    
  BL CD4 ≥200                                                          202     71.3          198     59.6           11.7 \[2.4-21.0\]
                                                                                                                    
  **VL \<50cpm (sensitivity analyses)**                                                                             
                                                                                                                    
  TLOVR non-VF censored                                                270     87.4          245     80.8           6.6 \[0.3-12.9\]
                                                                                                                    
  On protocol TLOVR                                                    340     69.1          345     57.1           12.0 \[4.8-19.2\]
                                                                                                                    
  Missing=failure                                                      343     68.5          346     60.1           8.4 \[1.3-15.5\]
                                                                                                                    
  FDA snapshot                                                         343     68.5          346     59.8           8.7 \[1.5-15.8\]
                                                                                                                    
  **Treatment-emergent adverse events (AEs)**                                                                       
                                                                                                                    
  AEs leading to permanent stop of study medication                    343     7.6           346     14.5           p=0.005\*
                                                                                                                    
  Grade 2-4 treatment-related diarrhoea                                343     5.0           346     11.3           p=0.003\*
                                                                                                                    
  **Changes in lipid parameters, median increase mmol/L (min; max)**                                                
                                                                                                                    
  Triglycerides^‡^                                                     254     0.1 (-5; 3)   228     0.6 (-3; 10)   p\<0.0001^¶^
                                                                                                                    
  Total cholesterol^§^                                                 254     0.6 (-2; 4)   228     1.0 (-1; 4)    p\<0.0001^¶^

\*Fisher\'s Exact test; ^‡^NCEP normal level \<1.69mmol/L; ^§^NCEP normal level \<5.17mmol/L; ^¶^Wilcoxon Rank Sum test

Conclusions
===========

DRV/r qd demonstrated sustained efficacy with non-inferiority and superiority to LPV/r over 192 wks. Development of resistance was low in both arms. DRV/r was associated with smaller median increases in total cholesterol and triglycerides than LPV/r, and a lower incidence of grade 2--4 diarrhoea.
